Mateon Therapeutics (NASDAQ: MATN) and Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.
Valuation & Earnings
This table compares Mateon Therapeutics and Jazz Pharmaceuticals PLC’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Mateon Therapeutics||N/A||N/A||-$14.59 million||($0.54)||-0.56|
|Jazz Pharmaceuticals PLC||$1.54 billion||5.71||$758.97 million||$6.45||22.71|
Jazz Pharmaceuticals PLC has higher revenue and earnings than Mateon Therapeutics. Mateon Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals PLC, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Mateon Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals PLC has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Insider & Institutional Ownership
8.6% of Mateon Therapeutics shares are owned by institutional investors. Comparatively, 88.3% of Jazz Pharmaceuticals PLC shares are owned by institutional investors. 2.3% of Mateon Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Jazz Pharmaceuticals PLC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a breakdown of recent ratings and price targets for Mateon Therapeutics and Jazz Pharmaceuticals PLC, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jazz Pharmaceuticals PLC||0||5||15||0||2.75|
Mateon Therapeutics currently has a consensus target price of $2.00, indicating a potential upside of 566.67%. Jazz Pharmaceuticals PLC has a consensus target price of $181.20, indicating a potential upside of 23.71%. Given Mateon Therapeutics’ higher probable upside, research analysts plainly believe Mateon Therapeutics is more favorable than Jazz Pharmaceuticals PLC.
This table compares Mateon Therapeutics and Jazz Pharmaceuticals PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jazz Pharmaceuticals PLC||25.69%||22.75%||9.14%|
Jazz Pharmaceuticals PLC beats Mateon Therapeutics on 9 of the 11 factors compared between the two stocks.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Receive News & Ratings for Mateon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.